DBVTF (DBV Technologies) Dividends Received


DBVTF DBV Technologies SA DBVTF
27 GF Score
Price $4.26
! 1 Warning Sign
View Full Analysis

What is DBV Technologies Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

DBVTF
27GF Score
DBV Technologies SA DBVTF
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DBV Technologies Business Description

Address 107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
27GF Score

Get the complete analysis for DBVTF

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.26
Price